Faeth Therapeutics (FTH) Total Liabilities (2020 - 2026)
Faeth Therapeutics' (FTH) quarterly Total Liabilities came in at $14.2 million in Q1 2026, up 125.76% YoY from $6.3 million in Q1 2025, and up 229.26% on a QoQ basis from $4.3 million in Q4 2025.
Faeth Therapeutics (FTH) Total Liabilities (2020 - 2026) Analysis & Trends
Faeth Therapeutics (FTH) has 7 years of Total Liabilities data on file, last reported at $14.2 million in Q1 2026.
- Quarterly Total Liabilities rose 125.76% year-over-year to $14.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $14.2 million (up 125.76% YoY) and the FY2025 annual result came in at $4.3 million, down 38.21% from the prior year.
- Total Liabilities grew to $14.2 million in Q1 2026, from $4.3 million in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $15.0 million in Q4 2022 to a low of $4.3 million in Q4 2025.
- A 5-year average of $9.7 million and a median of $9.5 million in 2023 frame the typical range for Total Liabilities.
- Annual changes were most pronounced in 2022 — Total Liabilities soared 356.89% — and 2025, when it plunged 41.25%.
- Tracing FTH's Total Liabilities over 5 years: stood at $15.0 million in 2022, then sank by 36.67% to $9.5 million in 2023, then fell by 26.42% to $7.0 million in 2024, then tumbled by 38.21% to $4.3 million in 2025, then surged by 229.26% to $14.2 million in 2026.
- The last three Total Liabilities figures came in at $14.2 million (Q1 2026), $4.3 million (Q4 2025), and $4.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.90 Bn | 131.05 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 86.10 Bn | 78.11 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 65.56 Bn | 60.37 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 55.82 Bn | 50.68 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 42.14 Bn | 37.04 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 31.67 Bn | 28.36 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 27.74 Bn | 9.35 Bn | 668.28 Mn | 3.22 Bn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | 1.35 Bn |
| 9 | Royalty Pharma | 27.38 Bn | 26.54 Bn | - | 10.03 Bn |
| 10 | Faeth Therapeutics | 179.96 Mn | 179.96 Mn | - | 9.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 9.58 Mn |
| Mar 31, 2026 | 14.19 Mn |
| Dec 31, 2025 | 4.31 Mn |
| Sep 30, 2025 | 4.58 Mn |
| Jun 30, 2025 | 4.47 Mn |
| Mar 31, 2025 | 6.29 Mn |
| Dec 31, 2024 | 6.98 Mn |
| Sep 30, 2024 | 7.48 Mn |
| Jun 30, 2024 | 7.61 Mn |
| Mar 31, 2024 | 8.22 Mn |
| Dec 31, 2023 | 9.48 Mn |
| Sep 30, 2023 | 10.66 Mn |
| Jun 30, 2023 | 10.38 Mn |
| Mar 31, 2023 | 13.08 Mn |
| Dec 31, 2022 | 14.97 Mn |
| Sep 30, 2022 | 14.82 Mn |
| Jun 30, 2022 | 12.12 Mn |
| Mar 31, 2022 | 14.73 Mn |
| Dec 31, 2021 | 6.71 Mn |
| Sep 30, 2021 | 6.04 Mn |